ES2042625T3 - Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular. - Google Patents

Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.

Info

Publication number
ES2042625T3
ES2042625T3 ES88104999T ES88104999T ES2042625T3 ES 2042625 T3 ES2042625 T3 ES 2042625T3 ES 88104999 T ES88104999 T ES 88104999T ES 88104999 T ES88104999 T ES 88104999T ES 2042625 T3 ES2042625 T3 ES 2042625T3
Authority
ES
Spain
Prior art keywords
intraocular pressure
blocking agent
adrenergic blocking
eye
prostaglandine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88104999T
Other languages
English (en)
Other versions
ES2042625T5 (es
Inventor
Laszlo Z Bito
Johan Wilhelm Stjernschantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Columbia University in the City of New York
Original Assignee
Pharmacia AB
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21876714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2042625(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia AB, Columbia University in the City of New York filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2042625T3 publication Critical patent/ES2042625T3/es
Publication of ES2042625T5 publication Critical patent/ES2042625T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN METODO PARA TRATAR LA HIPERTENSION OCULAS O EL GLAUCOMA EN EL OJO DE UN SUJETO. EL METODO COMPRENDE PONER EN CONTACTO LA SUPERFICIE DEL OJO CON UNA CANTIDAD EFECTIVA COMO REDUCTORA DE LA PRESION INTRAOCULAR DE UNA MEZCLA DE UN AGENTE BLOQUEANTE ADRENERGICO Y UNA PROSTAGLANDINA O UN DERIVADO DE ELLA EN UN VEHICULO OFTALMOLOGICAMENTE COMPATIBLE, DE FORMA QUE SE REDUZCA LA PRESION INTRAOCULAR DEL OJO Y LA MANTENGA REDUCIDA. ESTA INVENCION PRESENTA TAMBIEN UNA COMPOSICION PARA EL TRATAMIENTO DE LA HIPERTENSION OCULAR O DEL GLAUCOMA EN EL OJO DE UN SUJETO. LA COMPOSICION CONTIENE UNA CANTIDAD EFECTIVA COMO REDUCTORA DE LA PRESION INTRAOCULAR DE UNA MEZCLA DE UN AGENTE BLANQUEANTE ADRENERGICO Y UNA PROSTAGLANDINA O UN DERIVADO DE ESTA EN UN VEHICULO OFTALMOLOGICAMENTE COMPATIBLE.
ES88104999T 1987-04-03 1988-03-28 Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular. Expired - Lifetime ES2042625T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3448487A 1987-04-03 1987-04-03

Publications (2)

Publication Number Publication Date
ES2042625T3 true ES2042625T3 (es) 1993-12-16
ES2042625T5 ES2042625T5 (es) 2000-07-16

Family

ID=21876714

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88104999T Expired - Lifetime ES2042625T5 (es) 1987-04-03 1988-03-28 Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.

Country Status (9)

Country Link
EP (1) EP0286903B2 (es)
JP (1) JP2726672B2 (es)
AT (1) ATE76750T1 (es)
AU (1) AU607981B2 (es)
CA (1) CA1314220C (es)
DE (1) DE3871596T3 (es)
ES (1) ES2042625T5 (es)
GR (2) GR3004794T3 (es)
HU (1) HU211835A9 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5055467A (en) * 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5198545A (en) * 1989-11-13 1993-03-30 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof
US5011856A (en) * 1990-03-12 1991-04-30 Allergan, Inc. Use of prostaglandin F3 α as an ocular hypotensive agent
EP0458589B1 (en) * 1990-05-22 1995-01-18 R-Tech Ueno Ltd. Treatment of ocular hypertension with an ocular synergistic combination
DE69100171T2 (de) * 1990-05-22 1993-10-28 R Tech Ueno Ltd Synergistische Kombination zur ophthalmischen Verwendung.
US5166175A (en) * 1990-05-22 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination
US5238961A (en) * 1990-06-14 1993-08-24 Allergan, Inc. Pgf 1-alcohols and their use as ocular hypotensives
TW210287B (es) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
ES2166353T3 (es) * 1992-03-19 2002-04-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con beta-bloqueantes y derivados del acido prostanoico.
JPH06107547A (ja) * 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU674038B2 (en) * 1992-10-13 1996-12-05 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
DE69928771T2 (de) * 1998-01-23 2006-09-07 Einar Stefansson Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina
EP1386611A4 (en) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd MEDICINES AND MEDICAL KITS
TWI298257B (en) * 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
AU2007200821A1 (en) * 2001-05-31 2007-03-15 Allergan, Inc. Hypotensive lipid and timolol compositions and methods of using same
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
JP4972552B2 (ja) 2005-07-12 2012-07-11 興和株式会社 緑内障を予防又は治療する薬剤
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
CA2773597A1 (en) * 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9078854B2 (en) 2010-07-29 2015-07-14 Allergan, Inc. Preservative free bimatoprost and timolol solutions
TW202126308A (zh) 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN111479568A (zh) 2017-12-21 2020-07-31 参天制药株式会社 司培前列素与Rho激酶抑制剂的组合药物
EP3730143A4 (en) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. OMIDENEPAG COMBINATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454154A (en) * 1981-06-23 1984-06-12 American Hospital Supply Corporation Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3785602T2 (de) * 1986-03-13 1993-09-02 Univ Columbia Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.

Also Published As

Publication number Publication date
GR3004794T3 (es) 1993-04-28
EP0286903B2 (en) 2000-03-29
DE3871596T2 (de) 1993-01-21
GR3033721T3 (en) 2000-10-31
DE3871596D1 (de) 1992-07-09
JP2726672B2 (ja) 1998-03-11
ES2042625T5 (es) 2000-07-16
AU1387088A (en) 1988-10-06
EP0286903A1 (en) 1988-10-19
DE3871596T3 (de) 2000-09-07
HU211835A9 (en) 1995-12-28
ATE76750T1 (de) 1992-06-15
JPS63313728A (ja) 1988-12-21
CA1314220C (en) 1993-03-09
AU607981B2 (en) 1991-03-21
EP0286903B1 (en) 1992-06-03

Similar Documents

Publication Publication Date Title
ES2042625T5 (es) Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
ES2053458T3 (es) Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
ES2062102T3 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
IE811654L (en) Ophthalmic composition
ES2032390T3 (es) Composicion antihipertensiva ocular para uso topico. (reserva del art. 167.2 cpe).
PT89307A (pt) Aplicador de infusao e processo de preparacao de composicoes a base de (mono)oxicloroseno ou de oxicloroseno de sodio para o mesmo
EP0363469A4 (en) Lacrimal secretion stimulant (lss)
FI911131A (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
ES2141736T3 (es) Gel, especialmente para uso terapeutico ocular.
TW427913B (en) Eye drop composition comprising pilocarpine and a β-blocking agent and process making the same
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
DE69116224T2 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
DE69320329T2 (de) Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
DE69829062D1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
DE69301387D1 (de) Behandlung des Glaukoms mit synergistischer Kombination
KR880001290A (ko) β-차단제 및 필로카르핀-함유 제제
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
HU9301364D0 (en) Homo-prostaglandines applicables for treatment of hypertension in eyes
WO1998001099A3 (en) Method of treating retinal ischemia and glaucoma
ES2088489T3 (es) Uso de prostaglandina f3alfa como agente ocular hipotensivo.
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 286903

Country of ref document: ES